Celltrion, Inc.
Celltrion is a KOSPI-listed (068270) biologics company based in Incheon and one of the world's largest biosimilar developers. Its denosumab biosimilar Stoboclo was approved in the European Union in February 2025, and the company presented its inflammatory bowel disease portfolio at UEG Week 2026.
| Headquarters | Incheon, South Korea |
|---|---|
| Listing | KOSPI:068270 |
| Lead asset / stage | Stoboclo (denosumab) Approved — European Union |
| Latest event | Celltrion announced presentation of its IBD portfolio at UEG Week 2026. |